Outcomes of general practice virtual clinics 2018/2019
| General practice ID number* | DM number on register† | % excluded diabetes review‡ | Patients reviewed in visit to practice | Treatment optimal no change needed | Type 2 remission diet requested | Intense lifestyle advice advised | Insulin initiation | SGLT2 inhibitor or GLP1 agonist | Monogenic diabetes diagnosed | Libre issued | Intractable/ terminal care the priority | Psych referral advised | Other medical specialty referral |
| 1 | 850 | 16 | 30 | 2 | 1 | 5 | 7 | 1 | 2 | 2 | – | 3 | 7 |
| 2 | 190 | 8.6 | 9 | 3 | – | 1 | 1 | 1 | – | 1 | 2 | – | – |
| 3 | 950 | 11.5 | 11 | 2 | – | – | – | 1 | – | – | 1 | – | – |
| 4 | 510 | 21.7 | 12 | 3 | – | 4 | 2 | 1 | – | – | – | 1 | – |
| 5 | 432 | 13.7 | 5 | – | 1 | 1 | – | 1 | – | – | – | – | 2 |
| 6 | 1075 | 20.6 | 5 | – | – | 3 | – | 1 | 1 | – | – | ||
| 7 | 590 | 13.4 | 18 | 7 | – | 2 | 4 | 2 | – | 1 | 1 | – | 1 |
| 8 | 145 | 10.6 | 6 | – | 1 | 2 | 1 | 1 | – | – | – | 1 | |
| 9 | 1057 | 16.4 | 9 | 1 | 4 | 1 | 1 | – | – | 1 | – | 1 | |
| 10 | 840 | 16.1 | 11 | 1 | 1 | 1 | 2 | – | 2 | – | 2 | 1 | – |
| 11 | 280 | 8.1 | 14 | 3 | 7 | 2 | 1 | – | – | – | 1 | – | |
| 12 | 685 | 17.3 | 10 | 2 | 1 | 2 | 3 | 1 | – | – | – | – | 1 |
| 13 | 568 | 20 | 3 | – | – | 1 | – | 1 | – | – | – | 1 | |
| 14 | 795 | 17.8 | 13 | 4 | – | 2 | 2 | 1 | 1 | 1 | 1 | 1 | |
| 15 | 295 | 17.4 | 9 | 1 | 1 | 3 | 1 | 1 | 1 | – | – | – | 1 |
| 16 | 345 | 12.8 | 3 | 1 | – | – | 2 | – | – | – | – | – | – |
| 17 | 420 | 16 | 9 | 2 | 1 | 3 | – | 1 | 1 | – | – | 1 | – |
| Total | 10 616 | 15.2 | 175 | 32 | 7 | 34 | 29 | 19 | 8 | 6 | 9 | 9 | 15 |
*Each practice was given a sequential number 1–17.
†DM number means number of people with diabetes on each general practice QOF register.
‡In the NHS in England community physicians (general practitioners) report annual reviews of patients with long-term conditions including diabetes. Patients may be excluded from this QOF for a variety of reasons.
GLP1, glucagon-like peptide-1; GP, general practitioner; NHS, National Health Service; QOF, quality outcomes framework; SGLT2, sodium-glucose cotransporter-2 inhibitor.